Literature DB >> 17823640

Regression of radiation-induced macular edema after systemic bevacizumab.

Joel M Solano1, Sophie J Bakri, Jose S Pulido.   

Abstract

CASE REPORT: A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer. Eight months following EBR, he showed evidence of radiation retinopathy with macular edema. Optical coherence tomography (OCT) showed macular edema and subretinal fluid. Subsequently, systemic bevacizumab (5 mg/kg) was added to his leukovorin/5FU chemotherapy. After the addition of bevacizumab, OCT showed complete resolution of the macular edema and subretinal fluid. COMMENTS: Bevacizumab may have a role in the treatment of radiation retinopathy, but further investigation is needed before any definitive conclusions can be made.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823640     DOI: 10.3129/i07-140

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  4 in total

Review 1.  Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

Authors:  Rakesh K Jain
Journal:  Cancer Cell       Date:  2014-11-10       Impact factor: 31.743

Review 2.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Authors:  Rakesh K Jain
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

3.  Bevacizumab and intraocular tumors: an intriguing paradox.

Authors:  Mariam el Filali; Long V Ly; Gregorius P M Luyten; Mieke Versluis; Hans E Grossniklaus; Pieter A van der Velden; Martine J Jager
Journal:  Mol Vis       Date:  2012-10-05       Impact factor: 2.367

4.  Fellow Eye Macular Edema Improvement after Intravitreal Bevacizumab for Radiation Retinopathy.

Authors:  Isis A S Brito; Leandro C Zacharias; Sérgio Luis G Pimentel
Journal:  Case Rep Ophthalmol Med       Date:  2015-10-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.